Biogen Inc.
BIIBNASDAQHealthcare● Active
$192.62
$-2.72(-1.39%)
Market Cap$28.4B
P/E Ratio—
52W High$205.97
52W Low$121.05
Biogen Inc. (BIIB) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BIIB · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 29, 2026EPS Actual
$3.57
Est. $3.05 · +17.1%
Revenue
$2.48B
Est. $2.29B · +8.3%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 29, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 9-Quarter EPS Beat Streak
BIIB reports quarterly as a NASDAQ-listed Drug Manufacturers - General company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 30, 2026 | $3.18 | — | — | — | $2.43B | — |
| ▲ Q2 FY2026 | Apr 29, 2026 | $3.05 | $3.57 | +17.1% | $2.48B | $2.29B | +8.3% |
| ▲ Q1 FY2026 | Feb 6, 2026 | $1.63 | $1.99 | +22.1% | $2.28B | $2.20B | +3.5% |
| ▲ Q4 FY2025 | Oct 30, 2025 | $3.88 | $4.81 | +24.0% | $2.45B | $2.34B | +4.9% |
| ▲ Q3 FY2025 | Jul 31, 2025 | $3.90 | $5.47 | +40.3% | $2.65B | $2.33B | +13.6% |
| ▲ Q2 FY2025 | May 1, 2025 | $2.90 | $3.02 | +4.1% | $2.43B | $2.23B | +8.8% |
| — Q1 FY2025 | Feb 12, 2025 | $3.43 | $3.44 | +0.3% | $2.45B | $2.41B | +1.9% |
| ▲ Q4 FY2024 | Oct 30, 2024 | $3.77 | $4.08 | +8.2% | $2.47B | $2.43B | +1.3% |
Q3 FY2026
Jul 30, 2026
EPS Actual
—
EPS Est.
$3.18
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 29, 2026Beat
EPS Actual
$3.57
EPS Est.
$3.05
EPS Surpr.
+17.1%
Revenue
$2.48B
Q1 FY2026
Feb 6, 2026Beat
EPS Actual
$1.99
EPS Est.
$1.63
EPS Surpr.
+22.1%
Revenue
$2.28B
Q4 FY2025
Oct 30, 2025Beat
EPS Actual
$4.81
EPS Est.
$3.88
EPS Surpr.
+24.0%
Revenue
$2.45B
Q3 FY2025
Jul 31, 2025Beat
EPS Actual
$5.47
EPS Est.
$3.90
EPS Surpr.
+40.3%
Revenue
$2.65B
Q2 FY2025
May 1, 2025Beat
EPS Actual
$3.02
EPS Est.
$2.90
EPS Surpr.
+4.1%
Revenue
$2.43B
Q1 FY2025
Feb 12, 2025
EPS Actual
$3.44
EPS Est.
$3.43
EPS Surpr.
+0.3%
Revenue
$2.45B
Q4 FY2024
Oct 30, 2024Beat
EPS Actual
$4.08
EPS Est.
$3.77
EPS Surpr.
+8.2%
Revenue
$2.47B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $6.23 | $6.72 | $7.21 | 10 |
| Q3 FY2028 | $3.43 | $3.69 | $3.96 | 15 |
| Q2 FY2028 | $5.52 | $5.95 | $6.38 | 8 |
| Q1 FY2028 | $6.43 | $6.93 | $7.44 | 11 |
| Q4 FY2027 | $4.11 | $4.43 | $4.75 | 7 |
| Q3 FY2027 | $3.80 | $4.09 | $4.39 | 10 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $2.7B | $2.9B | $3.1B | 9 |
| Q3 FY2028 | $2.8B | $2.9B | $3.1B | 14 |
| Q2 FY2028 | $2.7B | $2.8B | $3.0B | 7 |
| Q1 FY2028 | $2.8B | $3.0B | $3.2B | 10 |
| Q4 FY2027 | $2.5B | $2.7B | $2.8B | 8 |
| Q3 FY2027 | $2.5B | $2.6B | $2.8B | 11 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 29, 2026 | +17.1% | $183.38 | $194.38 | +6.00% |
| ▲ Q1 FY2026 | Feb 6, 2026 | +22.1% | $185.36 | $201.18 | +8.53% |
| ▲ Q4 FY2025 | Oct 30, 2025 | +24.0% | $147.86 | $149.61 | +1.18% |
| ▲ Q3 FY2025 | Jul 31, 2025 | +40.3% | $126.64 | $128.00 | +1.07% |
| ▲ Q2 FY2025 | May 1, 2025 | +4.1% | $121.08 | $120.93 | -0.12% |
| ▲ Q1 FY2025 | Feb 12, 2025 | +0.3% | $139.39 | $133.43 | -4.28% |
| ▲ Q4 FY2024 | Oct 30, 2024 | +8.2% | $183.47 | $181.18 | -1.25% |
| ▲ Q3 FY2024 | Aug 1, 2024 | +29.7% | $213.20 | $210.70 | -1.17% |
Q2 FY2026+6.00%
Report Date
Apr 29, 2026
EPS Beat/Miss
+17.1%
Price Before
$183.38
Price After
$194.38
Q1 FY2026+8.53%
Report Date
Feb 6, 2026
EPS Beat/Miss
+22.1%
Price Before
$185.36
Price After
$201.18
Q4 FY2025+1.18%
Report Date
Oct 30, 2025
EPS Beat/Miss
+24.0%
Price Before
$147.86
Price After
$149.61
Q3 FY2025+1.07%
Report Date
Jul 31, 2025
EPS Beat/Miss
+40.3%
Price Before
$126.64
Price After
$128.00
Q2 FY2025-0.12%
Report Date
May 1, 2025
EPS Beat/Miss
+4.1%
Price Before
$121.08
Price After
$120.93
Q1 FY2025-4.28%
Report Date
Feb 12, 2025
EPS Beat/Miss
+0.3%
Price Before
$139.39
Price After
$133.43
Q4 FY2024-1.25%
Report Date
Oct 30, 2024
EPS Beat/Miss
+8.2%
Price Before
$183.47
Price After
$181.18
Q3 FY2024-1.17%
Report Date
Aug 1, 2024
EPS Beat/Miss
+29.7%
Price Before
$213.20
Price After
$210.70
Avg Beat Reaction+1.24%
Beat Rate8 / 8 quarters
Largest Move+8.53% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BIIB ends December
Biogen Inc. (BIIB) most recently reported earnings on April 29, 2026 for Q2 FY2026, posting EPS of $3.57 — beating the analyst consensus of $3.05 by +17.1%. BIIB has beaten EPS estimates for 9 consecutive quarters. The next BIIB earnings date is expected around September 1, 2026.
Each quarter, investors track BIIB earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BIIB revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BIIB's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BIIB earnings · 5 questionsBiogen Inc.'s next earnings report is expected around September 1, 2026. BIIB typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BIIB historically reports after market close (AMC).
BIIB earnings datewhen is BIIB earningsBIIB next earnings datewhen does BIIB report earningsBIIB earnings calendar
▸ Source: FMP · Biogen Inc. SEC filings · US GAAP · Biogen Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026